TrialClinical transplantation2025

A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation.

Patricia M Campbell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.